In this population of postoperative dogs breathing either room air or with nasal oxygen insufflation, PaO2 /FiO2 and SaO2 /FiO2 had excellent correlation. Further evaluation into the correlation between SaO2 /FiO2 or pulse oximeter oxygen saturation (SpO2 )/FiO2 with PaO2 /FiO2 in both healthy dogs, and dogs with pulmonary dysfunction is warranted.

No abstract

We described the use of IV nitroglycerin as adjunctive therapy in three canine patients with left congestive heart failure secondary to degenerative mitral valve disease. All three dogs were admitted for signs of respiratory distress and all were determined to be in left congestive heart failure by history, exam findings, thoracic radiographs, and echocardiography. In addition to standard therapy for left congestive heart failure, IV nitroglycerin was administered as a constant rate infusion at a dose of 1–6 mcg/kg/min. No adverse events attributable to the drug were noted. This is the first reported use of IV nitroglycerin in clinical veterinary patients. Further studies are warranted to investigate the safety, efficacy, and optimal dosing of IV nitroglycerin infusions in dogs with left congestive heart failure.